X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement aims for the use of EmendoBio’s novel OMNI-A4 nuclease to accelerate the manufacture and development of Anocca’s deep pipeline of TCR-T cell therapies for difficult-to-treat solid cancers.
Lead Product(s): TCR-T Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Recipient: Emendo Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 14, 2024
Details:
The financing will develop the company's unique process that enables discovery and manufacture of next generation TCR-T-based cell therapies for cancer on an industrial scale. The financing also allows Anocca to progress the company's first products into clinical trials.
Lead Product(s): TCR-T-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AMF
Deal Size: $36.5 million Upfront Cash: Undisclosed
Deal Type: Financing May 31, 2023
Details:
Anocca is using its advanced technologies to engineer next generationTCR-modified T-cell Therapy for the treatment of solid tumours with unmatched precision, speed, and scale.
Lead Product(s): TCR-modified T-cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: European Investment Bank
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing December 21, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
